SEC Filing: Form 10-Q
Quarterly report [Sections 13 or 15(d)]
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
Quarterly report [Sections 13 or 15(d)]
Current report
Current report
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Other definitive proxy statements